Abstract: The method includes: A first electronic device displays a control center on a first interface, where the control center includes a device list including one or more electronic devices, and the one or more electronic devices and the first electronic device are in a same content continuation system. The first electronic device receives a first selection operation of selecting a second electronic device from the one or more electronic devices by a user. In response to the first selection operation, the first electronic device determines whether the first electronic device is a source device or a target device of a current content continuation task. If the first electronic device is the target device of the current content continuation task, the first electronic device switches content in the second electronic device to the first electronic device for continuous playing.

Abstract: The method includes: A first electronic device displays a control center on a first interface, where the control center includes a device list including one or more electronic devices, and the one or more electronic devices and the first electronic device are in a same content continuation system. The first electronic device receives a first selection operation of selecting a second electronic device from the one or more electronic devices by a user. In response to the first selection operation, the first electronic device determines whether the first electronic device is a source device or a target device of a current content continuation task. If the first electronic device is the target device of the current content continuation task, the first electronic device switches content in the second electronic device to the first electronic device for continuous playing.

Abstract: The present invention discloses a novel polypeptide—human actin-binding protein 54 and a polynucleotide encoding the same, as well as a method of producing the polypeptide by DNA recombinant technology. The present invention also discloses methods of using the polypeptide in treatment of various diseases, such as malignant tumor, blood disease, HIV infection, immunological diseases and various inflammation. The present invention also discloses an antagonist against the polypeptide and the therapeutic use of the same. The present invention also discloses the use of such polynucleotide encoding human actin-binding protein 54.

Abstract: The invention disclosed a new kind of polypeptide-phosphatidic acid phosphatase 29.81 and the polynucleotide encoding said polypeptide and a process for priducing the polypeptide by DNA recombinant methods. It also disclosed the method of applying the polypeptide for the treatment of various kinds of diseases, such as peripheral nervous demyelination, night blindness, rachitis, fatty liver, bronchial asthma and peptic ulcer. The antagonist of the polypeptide and therapeutic use of the same is also disclosed. In addition, it refers to the use of polynucleotide encoding said phosphatidic acid phosphatase 29.81.

Abstract: Novel human polyadenylation binding Protein 20.13 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique, and methods for treating many diseases e.g. disorder of embryo development, growth developmental disturbant diseases etc. The invention also discloses antagonists against the polypeptide.

Abstract: The invention discloses a novle human vacuolar H+-ATPase C subunit 42 and a polynucleotide encoding it. The invention also concerns a process of producing the polypeptide by recombinant DNA techniques. Methods are also disclosed for treating many diseases, e.g. malignant tumors, hemopathies, HIV infections, immune diseases and inflammations utilizing the ploypeptide. The invention discloses antagonists of the polypeptide and therapeutics comprising the same. The invention also discloses the uses of the polynucleotide, which encodes the human vacuolar H+-ATPase C subunit 42.

Abstract: The present invention discloses a novel polypeptide, a steroid dehydrogenase 34, the polynucleotide encoding the polypeptide and the method for producing the polypetide by DNA recombinant technology. The invention also discloses the uses of the polypeptide in methods for tresting various diseases, such as steroid hormone dysbolismus disease, such as sex dysgenopathy, some endocrine and metabolic syndrome, viarous tumors of human reproductive system, bile acid dysbolismus, etc. The invention also discloses the agonists against the polypeptide and the therapeutic action thereof. The invention also discloses the uses of the polynucleotide encoding the novel steroid dehydrogenase 34.

Abstract: A novel polypeptide-human retinoic acid-responsive protein 53.57 and a polynucleotide encoding the same, as well as a method of producing the polypeptide by DNA recombinant technique. The present invention also discloses methods of using the polypeptide in treatment of various disease, such as arhythmia, bronchial asthma, peptic ulcer, diabetes mellitus, tumor, developmental deformation of embryo and so on. Also disclosed are antagonists against the polypeptide and the therapeutic use of the same.

Abstract: The present invention discloses a novel polypeptide-Human SNARE protein 25 and polynucleotide encoding the same, as well as a method of producing the polypeptide by DNA recombinant technology. The present invention also discloses methods of using the polypeptide in treatment of various diseases, such as malignant tumor, blood disease, HIV infection, immunological disease and various inflammations. The present invention also discloses an antagonist against the polypeptide and the therapeutic use of the same. The present invention also discloses the use of such polynucleotide encoding Human SNARE protein 25.

Abstract: The invention discloses a new kind of RNA binding protein 33 and polynucleotide encoding the polypeptide and a process for producing the polypeptide by recombinant methods. It also discloses the method of applying the polypeptide for the treatment of various kinds of diseases, such as cancer, hemopathology, HIV infection, immune diseases and inflammation. The antibody and antagonist of the polypeptide and the therapeutic use of the same is also disclosed. In addition, it refers to the use of polynucleotide encoding said RNA binding protein 33.

Abstract: The present invention discloses a novel polypeptide-human galectin 15 and a polynucleotide encoding the same, as well as a method of producing the polypeptide by DNA recombinant technology. The present invention also discloses methods of using the polypeptide in treatment of various diseases, such as malignant tumor, blood disease, HIV infection, immunological disease and various inflammations. The present invention also discloses an antagonist against the polypeptide and the therapeutic use of the same.

Abstract: The present invention discloses a novel polypeptide-human SR splicing factor 52 and polynucleotide encoding the same, as well as a method of producing the polypeptide by DNA recombinant technology. The present invention also discloses methods of using the polypeptide in treatment of various disease, such as malignant tumor, blood disease, HIV infection, immunological disease and various inflammation. The present invention also discloses an antagonist againts the polypeptide and the therapeutic use of the same. The present invention also discloses the use of such polynucleotide encoding Human SR splicing factor 52.

Abstract: A new polypeptide, human zinc finger protein FPM315-17, the polynucleotide encoding it and a method for producing the polypeptide by DNA recombinant technology. The present invention further discloses a method for using the polypeptide or polynucleotide for treating various disorders, e.g., various tumors, nervous system disorders, hemopathy, developmental disorders, and HIV infections. The present invention also discloses an antagonist of the polypeptide and its therapeutic application.

Abstract: The invention discloses a new polypeptide-transcription factor XAP-2 protein 49.72, the polynucleotide encoding said polypeptide, and a process for producing the polypeptide by recombinant DNA technology, It also discloses methods of applying the polypeptide for the treatment of various diseases, such as fetation abnormality, tumor, diabetes, catamenia disharmony, peptic ulcer, arhythmia, anaemia, epilepsia. This invention also discloses antagonist against said polypeptide and thereof therapy uses. In addition, it refers to the use of said polynucleotide encoding this new transcription factor XAP-2 protein 49.72.

Abstract: The present invention discloses a new polypeptide-calcitonin 11, the polynucleotide encoding it and a method producing the polypeptide by recombinant DNA technology. The present invention further discloses a method using the polypeptide to treat various disorders, e.g. malignant neoplasm, hematopathy, HIV infection and immunological disease and various inflammation etc. The present invention also discloses agonists of the polypeptide and their therapeutic uses. The present invention further discloses the use of the polynucleotide encoding the new calcitonin 11.

Abstract: New polypeptide-human G-proteins, polynucleotides encoding the same, as well as methods of producing said polypeptides by recombinant DNA techniques. The present invention also discloses methods of using the polypeptide in diagnosis and treatment of various diseases, such as malignant tumor, blood diseases, HIV infection, immunological diseases and a wide variety of inflammations. The invention also discloses antagonists against the polypeptides and therapeutic uses thereof.

Abstract: The present invention discloses a novel polypeptide, a human binding protein 42, the polynucleotide encoding the polypeptide and the method for producing the polypeptide by DNA recombinant technology. The invention also discloses the uses of the polypeptide in methods for treating various diseases, such as malignant tumour, hemopathy. HIV infection, immunological disease, and various inflammation, etc. The invention also discloses the agonists against the polypeptide and the therapeutic action thereof. The invention also discloses the uses of the polynucleotide encoding the novel human calcium binding protein 42.

Abstract: The present invention discloses a novel polypeptide-human retinoic acid-responsive protein 53.57 and a polynucleotide encoding the same, as well as a method of producing the polypeptide by DNA recombinant technique. The present invention also discloses methods of using the polypeptide in treatment of various disease, such as arhythmia, bronchial asthma, peptic ulcer, diabetes mellitus, tumor, developmental deformation of embryo and so on. The present invention also discloses an antagonist against the polypeptide and the therapeutic use of the same. The present invention also discloses the use of such polynucleotide encoding human retinoic acid-responsive protein 53.57.

Abstract: The invention disclosed a new kind of NADP-dependent leukotriene B412-hydroxydehydrogenase-36 and the polynucleotide encoding said polypeptide and a process for producing the polypeptide by recombinant methods. It also disclosed the method of applying the polypeptide for the treatment of various kinds of diseases, such as inflammation and oxygen radical damage disease. The antagonist of the polypeptide and therapeutic use of the same is also disclosed. In addition, it refers to the use of polynucleotide encoding said NADP-dependent leukotriene B412-hydroxydrogenase-36.

Abstract: The invention disclosed a new kind of polypeptide-phosphatidic acid phosphatase 29.81 and the polynucleotide encoding said polypeptide and a process for priducing the polypeptide by DNA recombinant methods. It also disclosed the method of applying the polypeptide for the treatment of various kinds of diseases, such as peripheral nervous demyelination, night blindness, rachitis, fatty liver, bronchial asthma and peptic ulcer. The antagonist of the polypeptide and therapeutic use of the same is also disclosed. In addition, it refers to the use of polynucleotide encoding said phosphatidic acid phosphatase 29.81.